One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."
Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them.
Many of the coronavirus vaccines like it cold. Really cold. Sub-zero cold. Why is this the case? And how is the world handling this frigid requirement?
Israel paid a premium, locked in an early supply of Pfizer-BioNTech vaccines and agreed to share data from Israel's centralized trove of medical statistics. Privacy advocates have some misgivings.
The two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind.
The new deal effectively doubles the federal government's order from the company. Pfizer says the U.S. government has agreed to pay $1.95 billion for the additional doses.
The top military official with the federal vaccine effort spoke less than 24 hours after Moderna's COVID-19 vaccine became the second to receive an emergency use authorization from the FDA.
Pfizer and BioNTech's vaccine is the first to receive an emergency authorization from the Food and Drug Administration. Officials say it may be ready for widespread inoculations within days.
As FDA emergency use authorization of Pfizer and Moderna vaccines nears, airlines, FedEx and UPS prepare to transport millions of vials of life saving shots.
With the first COVID-19 vaccine doses expected to be shipped out within days, health care providers are scrambling to prepare for an unprecedentedly high-stakes vaccine rollout.
The vaccine produced by Pfizer and BioNTech is the first to be authorized by Canadian health officials. The decision makes Canada just the third country in the world to grant such an authorization.
The pharmaceutical giant and partner BioNTech announced Friday that they are submitting a formal request to the Food and Drug Administration, just days after the vaccine was shown to be 95% effective.
Albert Bourla, head of the pharmaceutical giant, discusses plans for distributing its vaccine, which it says is 95% effective, and explains the timing of his $5.6 mllion sale of Pfizer stock.
The vaccine was found to be 95% effective in an updated study analysis. Safety data required by the Food and Drug Administration showed no serious concerns, the company said.
One of the two leading vaccine candidates requires deep, deep freezing. Here's how communities are working to solve for this and how the new Moderna vaccine could help.
Pfizer's CEO sold $5.6 million worth of stock on Monday. The company says the stock sale was made as part of a preset plan. But NPR found irregularities about when the CEO entered into that plan.
Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.
If the company's vaccine candidate pans out, Americans can receive it for free under the deal. The arrangement is part of the U.S. government's push to have a vaccine widely available by January.
The pharmaceutical giant said it would be abandoning its neuroscience development programs and allocating its spending elsewhere. The move also means the company will lay off some 300 employees.
A county judge and the state supreme court ordered the state not to put the inmates to death. The larger case challenges lethal drugs. The other argues that the inmate is not sane.
The medication is the only one available to prevent an infected pregnant woman from passing the disease to a fetus. Pfizer says the shortage should be over in July.
The drugmaker was the "last remaining open-market source of drugs used in executions," The New York Times reported. Other U.S. and European firms had already blocked drugs from use in executions.
